Trump Administration Set to Link Prenatal Acetaminophen (Tylenol) Use to Autism Risk Despite Mixed Evidence

Publication Date: September 22, 2025

Overview

The Trump administration, led by President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr., is preparing to release guidance tying acetaminophen—the active ingredient in Tylenol—use during pregnancy to an increased risk of autism spectrum disorder (ASD) in children. This move comes amid ongoing scientific debate, with some studies suggesting associations between prenatal exposure and neurodevelopmental outcomes, while others, including sibling-controlled analyses, find no causal relationship. The announcement also proposes leucovorin, a form of folic acid, as a potential preventive measure or treatment, though evidence for this remains limited. Pregnant individuals are advised to consult healthcare providers before altering medication use, as untreated pain or fever can pose risks.

Facts

Acetaminophen, marketed as Tylenol, is the most commonly used over-the-counter pain and fever reliever during pregnancy, with over 50% of pregnant women worldwide reporting its use.
A 2024 study published in JAMA, using sibling control analyses from a large Swedish cohort, found no association between prenatal acetaminophen exposure and children’s risk of autism, ADHD, or intellectual disability after accounting for shared familial factors.
A 2025 Mount Sinai systematic review of 46 observational studies identified positive associations in 27 studies between prenatal acetaminophen and neurodevelopmental disorders like autism and ADHD, particularly in higher-quality research, but concluded the evidence is inconclusive on causation.
Historical context: Acetaminophen was classified as FDA Pregnancy Category B in 1979 based on animal studies showing no fetal risks, and it became widely recommended for pregnant women in the 1960s as a safer alternative to aspirin.
Autism prevalence has risen steadily since the 1990s, from about 1 in 150 children in 2000 to 1 in 36 in 2020 per CDC data, though diagnostic changes and increased awareness contribute to this trend; acetaminophen usage rates have remained relatively stable.
Lawsuits alleging prenatal acetaminophen caused autism were consolidated in federal court in 2023 but dismissed, with plaintiffs claiming failure to warn; state-level cases continue.

Perspectives

Trump Administration (via President Trump and HHS Secretary Robert F. Kennedy Jr.): Based on reviewed evidence, they assert acetaminophen during pregnancy is “a very big factor” in autism risk and recommend avoiding it except for high fevers, while promoting leucovorin as a potential intervention to mitigate folate-related deficiencies potentially exacerbating the issue.
Kenvue (Tylenol’s parent company, formerly part of Johnson & Johnson): The company maintains that “independent, sound science clearly shows that taking acetaminophen does not cause autism,” emphasizing continuous evaluation of data and concern over health risks to pregnant women from unsubstantiated claims.
U.S. Food and Drug Administration (FDA): The agency states there is no causal link between acetaminophen use during pregnancy and autism, based on ongoing reviews, and classifies it as safe when used as directed, advising against changes without medical consultation.
Centers for Disease Control and Prevention (CDC): No credible scientific evidence supports acetaminophen causing autism; observational studies show associations but not causation, often confounded by factors like parental neurodevelopmental traits.
Autism Speaks (autism advocacy organization): Research, including a 2024 analysis, indicates no causal link between Tylenol and autism; associations may stem from confounding variables like genetic predispositions rather than the drug itself.
Mount Sinai Researchers (led by Dr. Carlos Prada): Their 2025 study supports evidence of an increased risk of autism and ADHD from prenatal acetaminophen but stresses that “untreated pain or fever can also pose risks,” recommending judicious use and further mechanistic research.

Considerations

Updated federal guidelines on acetaminophen could lead to revised pregnancy warnings, potentially reducing usage short-term while prompting investment in alternative pain management research for long-term maternal health improvements.
Increased public scrutiny may accelerate funding for randomized controlled trials to clarify causation, addressing current reliance on observational data and informing global drug safety policies.
If associations hold, policy shifts might emphasize folate supplementation like leucovorin during pregnancy, though current evidence is preliminary and requires validation through clinical trials.
Broader neurodevelopmental research trends highlight multifactorial autism causes, including genetics and environment, potentially shifting focus from single agents to comprehensive prenatal care protocols.
Economic impacts on pharmaceutical companies could spur innovation in safer analgesics, while advocacy groups push for transparent labeling to empower informed decisions without causing undue alarm.